Key Findings
The global market for long-read DNA sequencers is anticipated to experience significant accelerated growth by 2035. This surge is primarily driven by the increasing demand for quality control within the biopharmaceutical sector, specifically the necessity for high-resolution genomic evaluation in cell and gene therapy workflows. Long-read sequencing is positioned as an indispensable tool for ensuring the safety and efficacy of these advanced therapeutic products.
Technical / Clinical Details
Long-read DNA sequencing, capable of reading extended DNA sequences rather than short fragments, offers distinct advantages in deciphering complex genomic structures and identifying structural variants that are difficult to detect with short-read sequencing. Cell and gene therapy workflows represent a key growth application area for long-read DNA sequencers. There is a growing need to characterize with high resolution the outcomes of genome editing (e.g., CRISPR/Cas9), viral vector integration sites into the host genome, and potential off-target effects. In CAR-T cell therapy, long-read sequencing is essential for tracking the precise integration of chimeric antigen receptor (CAR) constructs into the patient’s T-cell genome and assessing the copy number and stability of the integrated CAR gene. Furthermore, its ability to detect clonality associated with gene integration and unexpected structural variants (e.g., translocations or large deletions) that could affect therapeutic efficacy or safety is critically important for ensuring product quality and patient safety.
Background & Context
While cell and gene therapies are rapidly advancing due to their innovative therapeutic potential, regulatory authorities impose extremely stringent requirements regarding the accuracy of genetic modifications during the manufacturing process and the uniformity and safety of the final product. Traditional short-read sequencing has limitations in analyzing genomic repeat regions and complex structural variants, posing challenges for quality control in cell and gene therapy manufacturing. The evolution of long-read sequencing technology is key to overcoming these challenges and establishing new standards for meeting regulatory requirements, thereby accelerating the development and commercialization of cell and gene therapies.
Strategic Significance & Outlook
The long-read DNA sequencer market is expected to continue its robust growth, fueled by the further expansion of the cell and gene therapy sector and the application of rigorous quality control standards by regulatory bodies. As sequencing technology becomes more cost-effective and its throughput improves, more research institutions and biopharmaceutical companies will adopt this technology. This will lead to a more detailed elucidation of the safety and efficacy profiles of cell and gene therapies, ultimately increasing the number of innovative treatments delivered to patients. Long-read sequencing will become an indispensable pillar in quality assurance during the genome editing era.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments